146 related articles for article (PubMed ID: 37301728)
1. Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer.
Amonkar MM; Chase M; Myer NM; Wang T; Turzhitsky V; Spira A
Cancer Treat Res Commun; 2023; 36():100712. PubMed ID: 37301728
[TBL] [Abstract][Full Text] [Related]
2. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France.
Roset M; Amonkar M; Patel R; Lara N; Kothari S
Adv Ther; 2022 Mar; 39(3):1215-1229. PubMed ID: 35025060
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
[TBL] [Abstract][Full Text] [Related]
4. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain.
Garcia-Carbonero R; González Astorga B; Vidal Tocino R; Contreras Toledo D; Pericay C; Fernández Montes A; Falcó E; González Cordero M; Reina Zoilo JJ; Alonso V; Rodríguez Salas N; Gil-Raga M; Santos C; Páez D; Anton-Pascual B; Aguilar F; Morales P
Clin Transl Oncol; 2024 Apr; 26(4):864-871. PubMed ID: 37651021
[TBL] [Abstract][Full Text] [Related]
5. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
[No Abstract] [Full Text] [Related]
6. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L
Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294
[TBL] [Abstract][Full Text] [Related]
7. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
Tougeron D; Sueur B; Zaanan A; de la Fouchardiére C; Sefrioui D; Lecomte T; Aparicio T; Des Guetz G; Artru P; Hautefeuille V; Coriat R; Moulin V; Locher C; Touchefeu Y; Lecaille C; Goujon G; Ferru A; Evrard C; Chautard R; Gentilhomme L; Vernerey D; Taieb J; André T; Henriques J; Cohen R;
Int J Cancer; 2020 Jul; 147(1):285-296. PubMed ID: 31970760
[TBL] [Abstract][Full Text] [Related]
8. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab.
Saberzadeh-Ardestani B; Jones JC; Hubbard JM; McWilliams RR; Halfdanarson TR; Shi Q; Sonbol MB; Ticku J; Jin Z; Sinicrope FA
JAMA Netw Open; 2023 Feb; 6(2):e230400. PubMed ID: 36811859
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.
Zhu C; Han G; Wu B
BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934
[TBL] [Abstract][Full Text] [Related]
11. Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with
Peeters M; Forget F; Karthaus M; Valladares-Ayerbes M; Zaniboni A; Demonty G; Guan X; Rivera F
ESMO Open; 2018; 3(2):e000297. PubMed ID: 29531837
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of Lynch syndrome, BRAF
Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
[TBL] [Abstract][Full Text] [Related]
14. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
Front Immunol; 2022; 13():795972. PubMed ID: 35371084
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
17. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
[TBL] [Abstract][Full Text] [Related]
18. KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer.
André T; Pietrantonio F; Avallone A; Gumus M; Wyrwicz L; Kim JG; Yalcin S; Kwiatkowski M; Lonardi S; Zolnierek J; Odeleye-Ajakaye A; Leconte P; Fogelman D; Kim TW
Future Oncol; 2023 Dec; 19(37):2445-2452. PubMed ID: 37701986
[TBL] [Abstract][Full Text] [Related]
19. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
20. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
Le DT; Kim TW; Van Cutsem E; Geva R; Jäger D; Hara H; Burge M; O'Neil B; Kavan P; Yoshino T; Guimbaud R; Taniguchi H; Elez E; Al-Batran SE; Boland PM; Crocenzi T; Atreya CE; Cui Y; Dai T; Marinello P; Diaz LA; André T
J Clin Oncol; 2020 Jan; 38(1):11-19. PubMed ID: 31725351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
